Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of COVID-19 Influenza Combination Vaccine in Older Adults
NCT06291857Phase 3Completed
- Sponsor
- Novavax
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of qNIV + CoV2373 in coronavirus disease 2019 (COVID-19), influenza, sponsored by Novavax. Started Dec 2024; status: completed.
02
Drugs
qNIV + CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06291857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291857.